

# Management of Patients with Multiple Sclerosis within Health-System Specialty Pharmacies

Autumn D Zuckerman<sup>1</sup>, Josh DeClerq<sup>1</sup>, Aimee Banks<sup>1</sup>, Abbi Blevins<sup>2</sup>, Elizabeth Rightmier<sup>3</sup>, Dana Simonson<sup>4</sup>, Evan Turco<sup>2</sup>, Julie Wawrzyniak<sup>3</sup>, Alicia L Zagel<sup>4</sup>, Leena Choi<sup>1</sup>

## Quick Facts

Multisite prospective cohort analysis to evaluate adherence, persistence, patient-reported outcomes, and pharmacist actions for patients prescribed a disease-modifying therapy for multiple sclerosis (MS) at an health-system specialty pharmacy (HSSP).

### Evaluated



**968**

patients  
prescribed  
DMT for MS



**10,562**

prescriptions  
filled




Across  
**4**  
sites



**6,940**

patient-reported  
outcomes (PRO)  
assessments

### Adherence and Persistence



**97%**

median  
adherence



**86%**

persistent  
over 1 year

Patients who switched disease-modifying therapies (DMTs) over the 1-year follow-up were more likely to have lower adherence and were less likely to be persistent

<sup>1</sup>Vanderbilt University Medical Center; <sup>2</sup>West Virginia University Medicine Specialty Pharmacy Services, Allied Health Solutions; <sup>3</sup>University of Rochester Specialty Pharmacy, UR Medicine; <sup>4</sup>Fairview Specialty Pharmacy

## Patient-Reported Outcomes



14.6%

of patients reported  
impacted productivity  
as a result of MS



4.7%

Low rates  
of relapse



1.9%

Low rates  
of MS-related  
hospitalization

## Pharmacist Actions



3,683

pharmacist  
actions performed



4

median  
actions  
per patient



43%

general  
medication  
education



33%

safety

Most common actions performed

Patients who reported impacted productivity had more pharmacist actions ( $p < 0.001$ )

- Patients serviced by HSSPs benefited from high rates of DMT adherence and persistence. They also reported low rates of impacted productivity, relapse and hospitalization.
- Patients switching DMTs had lower adherence and persistence. Additional care coordination or providing resources may optimize therapy transitions. They also reported issues with productivity, so those taking certain DMTs may require more frequent pharmacist actions.

Scan the code  
for more  
information



Zuckerman AD, DeClercq J, Simonson D, et al. Adherence and persistence to self-administered disease-modifying therapies in patients with multiple sclerosis: A multisite analysis. *Mult Scler Relat Disord*. 2023;75:104738. doi:10.1016/j.msard.2023.104738

Zuckerman AD, Banks AM, Wawrzyniak J, et al. Patient-reported outcomes and pharmacist actions in patients with multiple sclerosis managed by health-system specialty pharmacies [published online ahead of print, 2023 Aug 9]. *Am J Health Syst Pharm*. 2023;zxad180. doi:10.1093/ajhp/zxad180